Assembly Biosciences (ASMB) Long-Term Investments (2015 - 2022)

Assembly Biosciences' Long-Term Investments history runs 6 years deep, the most recent figure standing at $11.7 million for Q4 2022.

• In Q4 2022, Long-Term Investments fell 58.02% year-over-year to $11.7 million; the TTM figure through Dec 2022 stood at $11.7 million (down 58.02% YoY), while the FY2022 annual figure was $11.7 million, down 58.02% from the prior year.
• Long-Term Investments was $11.7 million for Q4 2022 at Assembly Biosciences, down from $11.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $28.0 million in Q4 2021 to a low of $2.2 million in Q2 2018.
• Historically, Long-Term Investments has averaged $14.4 million across 3 years, with a median of $11.8 million in 2022.
• The sharpest annual moves came in 2018 and 2022: Long-Term Investments fell 26.75% in 2018, then plunged 58.02% in 2022.
• A 3-year view of Long-Term Investments shows it stood at $2.2 million in 2018, then surged by 1169.09% to $28.0 million in 2021, then slumped by 58.02% to $11.7 million in 2022.
• The last three Long-Term Investments figures came in at $11.7 million (Q4 2022), $11.9 million (Q2 2022), and $23.5 million (Q1 2022), per Business Quant data.